Business
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
First subject enrolled into the OPMD clinical development program HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC)
About this update from Benitec Biopharma Inc.
[{"type":"text","content":"First subject enrolled into the OPMD clinical development program\nHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (\"ddRNAi\") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission. “In January, we were excited to announce the enrollment of the first OPMD patient into the natural history phase of the BB-301 development program, and the screening process has continued at a rapid pace. The enrollment of the first patient supports our central clinical development goal of administering the first dose of BB-301 and reporting interim clinical results in 2023,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. Dr. Banks continued, “The OPMD Natural History (NH) Study represents the 6-month pre-treatment observation period for each OPMD subject prior to the administration of BB-301 for the treatment of OPMD-related dysphagia. Upon the completion of 6-months of radiographic and clinical assessments required for the NH Study, participants will be eligible for enrollment into the BB-301 Phase 1b/2a treatment study in which BB-301 will be administered.” Operational Updates The key milestones related to the development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), along with other corporate updates, are outlined below: BB-301 Clinical Development Program Overview: The BB-301 clinical development program will be conducted in the United States, Canada, and France, and the primary elements of the program are summarized below: The program will comprise approximately 76 weeks of follow-up which we anticipate will consist of: The OPMD Natural History (NH) Study: 6-month pre-treatment observation periods for the evaluation of baseline disposition and natural history of OPMD-derived dysphagia (swallowing impairment) in each study participant.Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escala...